Abstract:Transposons have emerged as promising vectors for gene therapy that can potentially overcome some of the limitations of commonly used viral vectors. Transposons stably integrate into the target cell genome, enabling persistent expression of therapeutic genes. Transposons have evolved from being used as basic tools in biomedical research to bona fide therapeutics. Currently, the most promising transposons for gene therapy applications are derived from Sleeping Beauty (SB) or piggyBac (PB). Stable transposition requires co-delivery of the transposon DNA with the corresponding transposase gene, mRNA, or protein. Stable transposition efficiency can be substantially increased by using "next-generation" transposon systems that combine codon-usage optimization with hyper-activating mutations in the SB or PB transposases. By virtue of their relatively large capacity, gene therapy applications with relatively large therapeutic transgenes, such as full-length dystrophin, can now be envisaged. The authors and others have shown that efficient and stable gene transfer can be achieved with these next-generation transposons in several clinically relevant primary cells, such as CD34+ hematopoietic stem/progenitor cells, T cells, and mesenchymal and myogenic stem/progenitor cells that are amenable for ex vivo transfection. Alternatively, in vivo transposon gene delivery has been explored using non-viral vectors or nanoparticles or in combination with viral vectors. The therapeutic potential of these SB- and PB-based transposons has been demonstrated in preclinical models that mimic the cognate human diseases. However, there are still challenges impeding clinical translation of transposons pertaining mainly to the typical limiting efficiencies of most non-viral transfection methods and the intrinsic DNA toxicity. Nevertheless, it is particularly encouraging that transposons have now been used in gene therapy clinical trials. In particular, transposon-engineered T cells expressing chimeric antigen receptors are starting to yield promising results in patients with hematological malignancies.

Applications of Sleeping Beauty Transposons for Nonviral Gene Therapy

Transposons: Moving Forward from Preclinical Studies to Clinical Trials

Recent developments in transposon-mediated gene therapy

Latest Advances for the Sleeping Beauty Transposon System: 23 Years of Insomnia but Prettier than Ever

Stable Gene Transfer and Expression in Human Primary T Cells by the Sleeping Beauty Transposon System

Synergetic Targeted Delivery of Sleeping‐Beauty Transposon System to Mesenchymal Stem Cells Using LPD Nanoparticles Modified with a Phage‐Displayed Targeting Peptide

Sleeping Beauty Transposon‐Mediated Stable Gene Delivery

Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.

Gene repair and transposon-mediated gene therapy

Sleeping Beauty Transposon Insertions into Nucleolar DNA by an Engineered Transposase Localized in the Nucleolus

Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy

Endothelial targeting of the Sleeping Beauty transposon within lung

DNA-Based Nonviral Gene Therapy─Challenging but Promising.

RNA-guided retargeting of Sleeping Beauty transposition in human cells

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects

Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency

Stable Gene Transfer and Expression in Cord Blood–derived CD34+ Hematopoietic Stem and Progenitor Cells by a Hyperactive Sleeping Beauty Transposon System

Pharmaceutical strategies enhancing cell penetration efficiencies of non-viral gene delivery systems.

Electroporation markedly improves Sleeping Beauty transposon-induced tumorigenesis in mice

High-performance gene expression and knockout tools using sleeping beauty transposon system

Non-viral Gene Delivery Using Nanoparticles